Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Qiagen (NYSE:QGEN)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Qiagen (NYSE:QGEN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,148,281 shares of the company's stock, valued at approximately $95,746,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.97% of Qiagen as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. raised its position in Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in shares of Qiagen by 3.6% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after purchasing an additional 341 shares during the last quarter. Pitcairn Co. raised its holdings in Qiagen by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company's stock valued at $312,000 after buying an additional 354 shares during the period. Headlands Technologies LLC lifted its position in Qiagen by 2.0% in the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock valued at $883,000 after buying an additional 397 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its stake in Qiagen by 0.5% during the fourth quarter. Moors & Cabot Inc. now owns 86,474 shares of the company's stock worth $3,851,000 after buying an additional 426 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Robert W. Baird boosted their price objective on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. UBS Group decreased their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Qiagen has a consensus rating of "Hold" and an average price target of $48.42.

Qiagen Stock Performance

NYSE:QGEN traded up $0.13 during midday trading on Friday, reaching $45.13. The stock had a trading volume of 2,518,914 shares, compared to its average volume of 1,165,112. The stock has a market cap of $10.03 billion, a P/E ratio of 125.66, a P/E/G ratio of 2.39 and a beta of 0.67. The firm has a fifty day simple moving average of $41.59 and a two-hundred day simple moving average of $41.85. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. Qiagen has a 12-month low of $37.63 and a 12-month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Qiagen's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.44 earnings per share. On average, equities analysts expect that Qiagen will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.